Get the Stockscreener App
2.10
0.48%
0.01
After Hours:
2.11
0.010
+0.48%
Lipocine Inc stock is traded at $2.10, with a volume of 32,708.
It is up +0.48% in the last 24 hours and down -2.33% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$2.09
Open:
$2.12
24h Volume:
32,708
Relative Volume:
0.87
Market Cap:
$17.31M
Revenue:
$2.00M
Net Income/Loss:
$-11.43M
P/E Ratio:
-1.0731
EPS:
-1.957
Net Cash Flow:
$-10.05M
1W Performance:
-4.98%
1M Performance:
-2.33%
6M Performance:
-71.74%
1Y Performance:
-21.64%
1-Day Range:
$2.06
$2.1824
1-Week Range:
$2.06
$2.25
52-Week Range:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.10 | 17.31M | 2.00M | -11.43M | -10.05M | -1.957 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-06-26 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine Inc. (LPCN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Lipocine stock price target maintained at $4 by H.C. Wainwright - Investing.com Nigeria
LPCN Reiterated by HC Wainwright & Co. -- Price Target Announced at $4.00 - GuruFocus
HC Wainwright & Co. reiterates Neutral rating on Lipocine, $4 price target - TradingView
H.C. Wainwright Maintains Lipocine(LPCN.US) With Hold Rating, Announces Target Price $4 - Moomoo
Why Lipocine Inc. (NASDAQ:LPCN) Is In Focus Now? - Kalkine Media
Lipocine Inc.Common Stock (Nasdaq:LPCN) Stock Quote - The Chronicle-Journal
Lipocine (NASDAQ: LPCN) shares slides from New York investor conference - Stock Titan
LPCN: LPCN 1154 is poised to set a new standard in rapid, well-tolerated postpartum depression therapy - TradingView
Lipocine starts second Phase III for postpartum depression drug after first trial misses endpoint - AllSci
Lipocine initiates phase 3 trial for postpartum depression drug - Investing.com
Lipocine initiates phase 3 trial for postpartum depression drug By Investing.com - Investing.com Canada
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression - PR Newswire
Lipocine Launches Phase 3 BLOOM Study for PPD - TipRanks
Lipocine launches BLOOM Phase 3 study of LPCN 1154 for PPD; plans ~120 patients, expects $1M/mo cash use - TradingView
Form 8K Lipocine Inc For: 14 September By Investing.com - Investing.com UK
Lipocine starts Phase 3 trial for oral postpart... - Pluang
Form 8K Lipocine Inc For: 11 September By Investing.com - Investing.com Australia
Lipocine Stock Price Forecast. Should You Buy LPCN? - StockInvest.us
Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates - Kalkine
Lipocine updates sales agent fee agreement with A.G.P./Alliance Global Partners - Investing.com
Lipocine Cuts ATM Sales Agent Fee to Up to 3.0% - Minichart
Lipocine Updates Sales Agreement Fee Structure with A.G.P. - TipRanks
Lipocine (LPCN) sets sales agent commissions at up to 3% - Stock Titan
Form 8K Lipocine Inc For: 10 September By Investing.com - Investing.com South Africa
Lipocine to present at H.C. Wainwright conferen... - Pluang
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Lipocine to Present at H.C. Wainwright Investment Conference - TipRanks
Form 8K Lipocine Inc For: 10 September - Investing.com India
Webcast to highlight Lipocine (LPCN) oral drug pipeline - Stock Titan
Lipocine (LPCN) Advances 3.06% to $2.35, Testing Key Resistance ZoneSeasonality Effect - vinanet.vn
Lipocine (LPCN) Jumps 5.35% to $2.27 as Buyers Target $2.38 ResistanceSmart Money Flow Stocks - careplusvn.com
Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight - Yahoo Finance
Lipocine (LPCN) Q2 2026 Results: The Bottom-Line Figure Beats Its Comparison for the Current Session; After Results: The Share Price Moves Only Slightly under the Current SnapshotGross Profit Margin - vinanet.vn
Lipocine (LPCN) adds Grissinger to pay panel at $7,500 a year - Stock Titan
Lipocine (LPCN) Q2 2026 Scorecard: EPS Comes in Above Forecast in Latest Trading; Price Reaction - vinanet.vn
Lipocine (LPCN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations in Latest Trading; Immediate Response: The Stock Ends Down 0.49% in the Current UpdateEarnings Preview - dars.gov.et
Lipocine Inc. (LPCN) Edges Higher to $2.12, Holding Above Key SupportAdvance Decline Volume - dars.gov.et
Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake - Stock Titan
LPCN Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus as Revenue Remains Absent - vinanet.vn
Weekly Recap: Q2 revenue drop and Brilzio partner search - TradingView
LPCN Q2 2026 Earnings: Loss Narrower Than Expected, Shares Ease 1.41%Energy Earnings Report - careplusvn.com
Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options - Stock Titan
Lipocine Inc. (LPCN) director Grissinger files initial ownership statement - Stock Titan
Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Lipocine files Form 3 initial beneficial ownership statement for director Michael Grissinger - Bitget
Lipocine Inc (LPCN) Stock News Today - TradingKey
LPCN Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage SpendingEstimate Uncertainty - careplusvn.com
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Lipocine (LPCN) and High Tide (HITI) - The Globe and Mail
Lipocine (LPCN) Slips 1.8% to $2.13 as Biotech Stock Holds Above Key $2.02 SupportOvervalued Signals - dars.gov.et
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):